Webinar

Modelling human neurodegenerative diseases in research & drug discovery

The ability to efficiently produce disease-specific human cell models consistently at scale opens vast opportunities to study neurodegeneration in vitro. This webcast will describe how a new class of precision, reprogrammed human disease models, are being incorporated into high throughput screens and drug discovery workflows.
Modelling human neurodegenerative diseases in research & drug discovery

Dr Mariangela Iovino | Group Leader | Charles River

Modelling human neurodegenerative diseases in research & drug discovery
The ability to efficiently produce disease-specific human cell models consistently at scale opens vast opportunities to study neurodegeneration in vitro. This webcast will describe how a new class of precision, reprogrammed human disease models, are being incorporated into high throughput screens and drug discovery workflows.
Modelling human neurodegenerative diseases in research & drug discovery

Dr Mariangela Iovino | Group Leader | Charles River

With a paucity of successful treatments for neurodegenerative diseases, there remains an urgent need to improve research outcomes and drug discovery efficiencies.

It remains challenging to source physiologically-relevant CNS models that are both scalable and reproducible.

Use of human induced Pluripotent Stem Cell (iPSC)-derived neurons offers a relevant model system, but can be hindered by low scalability, heterogeneous populations and long, complex protocols.A next-generation cell reprogramming technology, opti-ox™, aims to resolve the inconsistencies and inefficiencies of current cell generation methods to enable the precise, consistent and scalable production of human cells. This technology has been used to develop a range of iPSC-derived ioGlutamatergic Neurons carrying disease-specific mutations. The isogenic pairing offers an efficient and robust system using a simple protocol to study neurodegeneration in vitro.

This webcast describes how this new class of precision reprogrammed disease models, are being incorporated into high-throughput screens and drug discovery workflows.

You will learn about the:

  • Need for a new class of scalable isogenic disease models for CNS research and drug discovery
  • Development, characterisation and validation of human cell models with disease-relevant mutations
  • Incorporation of disease ioGlutamatergic Neurons into HTS workflows

 

2022

Dr Mariangela Iovino | Group Leader | Charles River

Dr Tony Oosterveen | Senior Scientist | bit.bio

Watch webinar

Related pages

News Read our latest updates and press coverage
Our platform Discover the cell identity coding platform behind our cells
Join us Explore the latest roles at bit.bio